Ikena Oncology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 43
- Market Cap
- $83.7M
- Website
- http://www.ikenaoncology.com
- Introduction
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, ...
Will the tide turn for the wave of pharma layoffs?
Pharma layoffs attributed to patent cliffs and US election uncertainty; CROs benefit from pharma downsizing; historical R&D layoffs contrast with past commercial-focused cuts; core functions like study monitoring and CMC targeted; future trends unpredictable due to global political and economic factors.
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3
S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.
© Copyright 2024. All Rights Reserved by MedPath